Intervention Review

You have free access to this content

Vaccines for preventing malaria (pre-erythrocytic)

  1. Patricia M Graves1,*,
  2. Hellen Gelband2

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 13 JUN 2006

DOI: 10.1002/14651858.CD006198

Database Title

Additional Information

How to Cite

Graves PM, Gelband H. Vaccines for preventing malaria (pre-erythrocytic). Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006198. DOI: 10.1002/14651858.CD006198.

Author Information

  1. 1

    EpiVec Consulting, Atlanta, Georgia, USA

  2. 2

    Resources for the Future, Washington, DC, USA

*Patricia M Graves, EpiVec Consulting, Atlanta, Georgia, GA 30341, USA. epivec@comcast.net. pmgraves@aol.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (60K)Standard (307K)Full (443K)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Alonso 2005a {published data only}
  • Alonso P, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004;364(9443):1411-20.
  • Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, et al. Duration of protection with RTS,S ASO2A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005;366(9502):2012-8.
Alonso 2005ab {published data only}
  • See Alonso 2005a, 2005b.
Alonso 2005b {published data only}
  • Alonso P, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and diseases in young African children: randomised controlled trial. Lancet 2004;364(9443):1411-20.
  • Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, et al. Duration of protection with RTS,S ASO2A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005;366(9502):2012-8.
Bojang 2001 {published data only}
  • Alloueche A, Milligan P, Conway DJ, Pinder M, Bojang K, Doherty T, et al. Protective efficacy of the RTS,S/ASO2 Plasmodium falciparum malaria vaccine is not strain specific. American Journal of Tropical Medicine and Hygiene 2003;68(1):97-101.
  • Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001;358(9297):1927-34.
Bojang 2005a {published data only}
  • Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitzpatrick S, et al. Safety and immunogenicity of RTS,S/ASO2A candidate malaria vaccine in Gambian children. Vaccine 2005;23(32):4148-57.
Bojang 2005b {published data only}
  • Bojang KA, Olodude F, Pinder M, Ofori-Anyinam O, Vigneron L, Fitspatrick S, et al. Safety and immunogenicity of RTS,S/ASO2A candidate malaria vaccine in Gambian children. Vaccine 2005;23(32):4148-57.
Brown 1994 {published data only}
  • Brown AE, Singharaj P, Webster HK, Pipithkul J, Gordon DM, Boslego JW, et al. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers. Vaccine 1994;12(2):102-7.
Genton 2005 {published and unpublished data}
  • Genton B, D'Acremont V, Lurati F, Verhage D, Hermsen R, Audran R, et al. Randomized, double-blind placebo-controlled Phase IIa trial to test efficacy of the malaria vaccine PfCS102 to protect non-immune volunteers against falciparum challenge. Acta Tropica 2005;Suppl 95:84.
Guiguemde 1990 {published data only}
  • Guiguemde TR, Sturchler D, Ouedraogo JB, Drabo M, Etlinger H, Douchet C, et al. Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso) [Vaccination contre le paludisme: premier essai avec un vaccin antisporozoite, le (NANP)3-TT (RO40-2361) en Afrique (Bobo-Dioulasso, Burkina Faso)]. Bulletin de la Societe de Pathologie Exotique 1990;83(2):217-27.
Kester 2001 {published data only}
  • Kester KE, McKinney DA, Tornieporth N, Ockenhouse C, Heppner DG, Hall T, et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. Journal of Infectious Diseases 2001;183(4):640-7.
Moorthy 2004b {published data only}
  • Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, et al. A randomised, double-blind controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLOS Medicine 2004;1(2):128-36.
Sherwood 1996 {published data only}
  • Sherwood JA, Copeland RS, Taylor KA, Abok K, Oloo AJ, Were JB, et al. Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria in Kenya. Vaccine 1996;14(8):817-27.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Bejon 2005 {published data only}
  • Bejon P, Andrews L, Andersen RF, Dunachie S, Webster D, Walther M, et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial polymerase chain reaction studies of volunteers challenged with malaria sporozoites. Journal of Infectious Diseases 2005;191(4):619-26.
Doherty 1999 {published data only}
  • Doherty JF, Pinder M, Tornieporth N, Carton C, Vigneron L, Milligan P, et al. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in the Gambia. American Journal of Tropical Medicine and Hygiene 1999;61(6):865-8.
Edelman 2002 {published data only}
  • Edelman R, Wasserman SS, Kublin JG, Bodison SA, Nardin EH, Oliveira GA, et al. Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 2002;21(3-4):269-80.
Epstein 2004 {published data only}
  • Epstein JE, Charoenvit Y, Kester K, Wang R, Newcomer R, Fitzpatrick S, et al. Safety, tolerability and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/ASO2A. Vaccine 2004;22(13-4):1592-603.
Fries 1992 {published data only}
  • Fries LF, Gordon DM, Schneider I, Beier J, Long GW, Gross M, et al. Safety, immunogenicity and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infection and Immunity 1992;60(5):1834-9.
Gordon 1990 {published data only}
  • Gordon DM, Cosgriff TM, Schneider I, Wasserman GF, Majarian WR, Hollingdale MR, et al. Safety and immunogenicity of a Plasmodium vivax sporozoite vaccine. American Journal of Tropical Medicine and Hygiene 1990;42(6):527-31.
Gordon 1995 {published data only}
  • Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, et al. Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. Journal of Infectious Diseases 1995;171(6):1576-85.
Heppner 1996 {published data only}
  • Heppner DG, Gordon DM, Gross M, Wellde B, Leitner W, Krzych U, et al. Safety, immunogenicity and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. Journal of Infectious Diseases 1996;174(2):361-6.
Hoffman 1994 {published data only}
  • Hoffman SL, Edelman R, Bryan JP, Schneider I, Davis J, Sedegah M, et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalene as adjuvant. American Journal of Tropical Medicine and Hygiene 1994;51(5):603-12.
Hoffman 2002 {published data only}
  • Hoffman SL, Goh ML, Luke TC, Schneider I, Le TP, Doolan DL, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. Journal of Infectious Diseases 2002;185(8):1155-64.
Le 1999 {published data only}
  • Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000;18(18):1893-901.
McConkey 2003 {published data only}
  • McConkey SJ, Reece WHH, Moorthy VS, Webster D, Dunachie S, Butcher G, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Medicine 2003;9(6):729-35.
Moorthy 2003 {published data only}
  • Moorthy VS, Pinder M, Reece WH, Watkins K, Atabani S, et al. Safety and immunogenicity of DNA modified vaccinia virus Ankara malaria vaccination in African adults. Journal of Infectious Diseases 2003;188(8):1239-44.
Moorthy 2004c {published data only}
  • Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, Skinner MA, et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. Journal of Infectious Diseases 2004;189(12):2213-9.
Nardin 2000 {published data only}
  • Nardin EH, Oliveira GA, Calvo-Calle JM, Castro ZR, Nussenzweig RS, Schmeckpeper B, et al. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. Journal of Infectious Diseases 2000;182(5):1486-96.
Nardin 2001 {published data only}
  • Nardin EH, Calvo-Calle JM, Oliveira GA, Nussenzweig RS, Schneider M, Tiercy JM, et al. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. Journal of Immunology 2001;166(1):481-9.
Roggero 1999 {published data only}
  • Roggero MA, Weilenmann C, Bonelo A, Audran R, Renggli J, Spertini F, et al. Plasmodium falciparium CS C-terminal fragment: preclinical evaluation and phase I clinical studies. Parassitologia 1999;41(1-3):421-4.
Stoute 1998 {published data only}
  • Nussenzweig R, Zavala F. A malaria vaccine based on a sporozoite antigen. New England Journal of Medicine 1997;336(2):128-30.
  • Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, et al. Long-term efficacy and immune response following immunization with the RTS,S malaria vaccine. Journal of Infectious Diseases 1998;178(4):1139-44.
  • Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S malaria vaccine evaluation group. New England Journal of Medicine 1997;336(2):86-91.
Walther 2005 {published data only}
  • Walther M, Dunachie S, Keating S, Vuola JM, Berthoud T, Schmidt A, et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 2005;23(7):857-864.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Ballou 2004
  • Ballou WR, Arrevalo-Herrera M, Carucci D, Richie TL, Corradin G, Diggs C, et al. Update on the clinical development of candidate malaria vaccines. American Journal of Tropical Medicine and Hygiene 2004;71 Suppl 2:239-47.
Breman 2004
  • Breman JG, Alilio MS, Mills A. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. American Journal of Tropical Medicine and Hygiene 2004;71 Suppl 2:1-15.
Graves 2006a
  • Graves P, Gelband H. Vaccines for preventing malaria (SPf66). Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: ]
Graves 2006b
  • Graves PM, Gelband H. Vaccines for preventing malaria (blood-stage). Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: ]
Hay 2004
Higgins 2005
  • Higgins J, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Appendix 5b. www.cochrane.org/resources/handbook/hbook.htm (accessed 1 September 2005).
Jüni 2001
Moorthy 2004a
Review Manager 5
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Richie 2002
Snow 2004
  • Snow RW, Korenromp E, Gouws E. Pediatric mortality in Africa: Plasmodium falciparum as a cause or risk?. American Journal of Tropical Medicine and Hygiene 2004;71 Suppl 2:16-24.
Snow 2005
WHO 2002
  • World Health Organization. The world health report : 2002 : Reducing the risks, promoting healthy life. Geneva: World Health Organization, 2002.
WHO 2005
  • World Health Organization. Initiative for Vaccine Research. Portfolio of candidate malaria vaccines currently in development: March 2005. www.who.int/vaccine_research/documents/en/malaria_table.pdf (accessed 3 May 2006).
View Full Article (HTML) Summary (60K)Standard (307K)Full (443K)